Lv1
60 积分 2024-03-17 加入
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
3小时前
求助中
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy
2个月前
已完结
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
2个月前
已完结
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
2个月前
已完结
The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis
2个月前
已完结
CAR T-cell therapy in autoimmune diseases
3个月前
已完结
Final Analysis Of Safety And Exploratory Echo Data In A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study To Evaluate JK07 In Subjects With Heart Failure With Reduced Ejection Fraction
3个月前
已完结
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
4个月前
已完结
Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial
5个月前
已关闭
皖公网安备34019202002308
